文献速递系统性红斑狼疮

LFA-REAL、SLEDAI与BILAG检测狼疮活动临床意义变化的性能比较

Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-04-10

这项前瞻性多中心观察研究纳入163例成人系统性红斑狼疮患者,在基线和随访时用LFA-REAL、SLEDAI和BILAG评估疾病活动度,并以CGIC为临床变化标准。LFA-REAL检测改善的AUC为0.85,优于BILAG的0.75和SLEDAI的0.74;检测恶化的AUC为0.86,与两者相当。在需升级治疗的8例恶化患者中,LFA-REAL全部识别出≥10 mm差异,BILAG和SLEDAI分别识别4例和2例。

要点

  • LFA-REAL检测CGIC定义改善的AUC为0.85,显著优于SLEDAI的0.74。
  • LFA-REAL检测恶化的AUC为0.86,与BILAG和SLEDAI性能相当。
  • 需升级治疗的恶化患者中,LFA-REAL全部识别,BILAG和SLEDAI识别较少。

核心结论

  • LFA-REAL检测临床医生评定的变化与SLEDAI和BILAG性能相当,检测改善时对SLEDAI有统计学显著优势。

研究设计与样本

  • 前瞻性观察研究,在四个中心纳入163例成人系统性红斑狼疮患者,145例完成随访。
  • 基线和随访时由同一医生用SLEDAI、BILAG和LFA-REAL评估疾病活动度,随访时记录CGIC分类为改善、恶化或稳定。
  • 采用受试者工作特征曲线分析评估各工具检测CGIC定义变化的能力,用Youden指数确定最佳截断点。

主要发现

  • 基于CGIC,23%患者改善,16%恶化,61%保持稳定。
  • 检测CGIC定义改善:LFA-REAL的AUC为0.85(95%CI 0.77-0.92),BILAG为0.75(95%CI 0.66-0.85),SLEDAI为0.74(95%CI 0.64-0.84)。
  • 检测CGIC定义恶化:LFA-REAL的AUC为0.86(95%CI 0.77-0.96),BILAG为0.79(95%CI 0.67-0.90),SLEDAI为0.76(95%CI 0.66-0.87)。
  • CGIC定义恶化的患者中,8例(35%)需要升级治疗;LFA-REAL识别出全部8例差异≥10 mm,BILAG识别4例,SLEDAI识别2例。

关键数值与推荐

  • LFA-REAL检测改善的AUC为0.85(95%CI 0.77-0.92),检测恶化的AUC为0.86(95%CI 0.77-0.96)。
  • BILAG检测改善的AUC为0.75(95%CI 0.66-0.85),检测恶化的AUC为0.79(95%CI 0.67-0.90)。
  • SLEDAI检测改善的AUC为0.74(95%CI 0.64-0.84),检测恶化的AUC为0.76(95%CI 0.66-0.87)。

临床怎么用

  • LFA-REAL可作为临床实践和研究中评估狼疮疾病活动度的指标,尤其在检测改善方面可能优于SLEDAI。
  • 对临床医生判定恶化且需升级治疗的患者,LFA-REAL显示较高识别能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to compare the performance of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL), British Isles Lupus Assessment Group Index (BILAG), and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in detecting the clinician's perception of improvement and worsening disease and identifying patients requiring treatment escalation. METHODS: This was a prospective, observational study conducted at four centers. Adults with systemic lupus erythematosus were evaluated at a baseline and follow-up visit. Disease activity was assessed using SLEDAI, BILAG, and LFA-REAL at both visits by the same physician. At the follow-up visit, the Clinician Global Impression of Change (CGIC) was recorded to classify patients as improved, worsened, or unchanged. Receiver operating characteristic curve analysis was used to evaluate each instrument in detecting clinician-rated change gauged by CGIC with optimal cut-off points determined using the Youden Index. RESULTS: Of the 163 patients enrolled, 145 (89%) completed a follow-up visit. Based on CGIC, 23% improved, 16% worsened, and 61% remained stable. For detecting CGIC-defined improvement, LFA-REAL had an area under the curve (AUC) of 0.85 (95% confidence interval [CI] 0.77-0.92), compared to 0.75 (95% CI 0.66-0.85) for BILAG and 0.74 (95% CI 0.64-0.84) for SLEDAI. For CGIC-defined worsening, AUCs were 0.86 (95% CI 0.77-0.96), 0.79 (95% CI 0.67-0.90), and 0.76 (95% CI 0.66-0.87). Of those with CGIC-defined worsening, eight (35%) required treatment escalation. LFA-REAL identified a difference of ≥10 mm in all eight of these patients, compared to four by BILAG and two by SLEDAI. CONCLUSION: LFA-REAL showed comparable performance relative to SLEDAI and BILAG in detecting clinician-rated change. There was a statistically significant advantage over SLEDAI for detection of improvement. These findings support its utility as a metric for disease activity in clinical practice and research.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Nordmann-Gomes A, Khalili L, Aranow C, et al. Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity. Arthritis Care Res (Hoboken). 2026. PMID: 41801044. doi:10.1002/acr.80034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。